Rezolute, Inc. (filing identifies registrant as AntriaBio, Inc.) — 10-Q Summary
Reporting period: Quarter ended September 30, 2015, filed November 16, 2015. This is the company’s fiscal first quarter of 2016, not calendar or fiscal Q1 2015. The filing describes AntriaBio, a preclinical biopharmaceutical company. The filing text does not explain the difference between the requested company name, Rezolute, Inc., and the registrant name, AntriaBio, Inc.
Financial results and position
| Metric | Quarter ended September 30, 2015 | Comparable 2014 quarter / other balance date |
|---|---|---|
| Revenue | None; the company had not generated revenue | None |
| Research and development expense | $1.97 million | $0.11 million |
| General and administrative expense | $1.33 million | $2.12 million |
| Total operating expenses | $3.30 million | $2.24 million |
| Net loss | $3.29 million; $0.14 per share | $2.21 million; $0.12 per share |
| Operating cash used | $2.51 million | $1.47 million |
| Cash | $2.35 million | $5.28 million at June 30, 2015 |
| Restricted cash | $0.45 million | $0.45 million at June 30, 2015 |
| Working capital | $1.10 million | Not stated for the comparable date |
| Total assets / total liabilities | $9.17 million / $2.41 million | $11.26 million / $2.21 million at June 30, 2015 |
Margins: Not meaningful because the company had no revenue. Cash declined by $2.93 million during the quarter. Investing activities used $0.39 million, primarily for fixed-asset purchases; financing activities used $0.02 million for lease payments. Fixed assets included $2.68 million of construction in progress.
Debt and obligations: The company reported $60,000 of convertible notes, matured and due, accruing interest at 8%. Current liabilities were $1.96 million. Lease commitments included $1.75 million of minimum rent under the facility lease and $93,870 of equipment lease payable.
Changes and business developments
- Net loss widened by approximately $1.07 million year over year, primarily as R&D expense rose with staffing, research activity, and preparation of clinical material. G&A declined as consulting and investor-relations work shifted in-house.
- Cash fell from $5.28 million at June 30 to $2.35 million at September 30. The filing attributes earlier funding to private placements completed during fiscal 2015, which generated approximately $10.1 million net proceeds.
- The company reported completion of six-week toxicology studies for AB101 in dogs and rats; final analysis and reports were expected by calendar year-end 2015. The cGMP suite construction was complete by November 13, with certifications being finalized.
- The company announced AB301, a proposed once-weekly combination of a GLP-1 agonist and AB101 for type 2 diabetes, and said preclinical work was ongoing.
Outlook, risks, and notable items
- FDA feedback requested at least six months of stability data for AB101 drug substance, rather than the one month the company had anticipated. Along with facility delays, this shifted expected IND filing to the end of the second quarter of calendar 2016 and clinical-study start to after FDA acceptance.
- Management estimated it would need approximately $15–$20 million to fund objectives through calendar 2016, including AB101 clinical material, IND filing and the first clinical study, plus AB301 preclinical work. It planned to raise additional capital but gave no assurance financing would be available on acceptable terms.
- The company stated that current cash and expected operating cash flows would not sustain operations for more than one year. The filing identifies substantial doubt about the company’s ability to continue as a going concern.
- Management concluded disclosure controls and procedures were ineffective due to a material weakness involving inadequate segregation of duties and a need for a stronger internal-control environment, attributed to the small staff.
- No material litigation, off-balance-sheet arrangements, or material changes to previously disclosed risk factors were reported. No income-tax provision was recorded.
Key facts for investors to verify
- Confirm the issuer identity and relationship between the requested Rezolute, Inc. and the AntriaBio, Inc. named in this filing.
- Track financing availability and terms against the stated $15–$20 million funding need and going-concern warning.
- Verify completion of cGMP certifications, AB101 stability data, and progress toward the revised IND and clinical-trial timeline.
- Assess the status and repayment or conversion of the matured $60,000 notes and the company’s lease obligations.
- Monitor remediation of the disclosed material weakness in disclosure controls and procedures.